IP Library Granted Patent US 7,732,489
Granted Patent B2
US 7,732,489 · App. 10/524,735 · Granted Jun 8, 2010

Topical emulsion-gel composition comprising diclofenac sodium

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,732,489
App. No.
10/524,735
Granted
Jun 8, 2010
Kind
B2
Abstract

The invention relates to beneficial topical pharmaceutical compositions comprising diclofenac sodium salt in unusually low amounts. The compositions represent opaque emulsion-gels, in which diclofenac is kept fully dissolved.

Claims (30)

1. A pharmaceutical topical use in the form of an emulsion gel consisting of:

(a) 0.1% (w/w) of diclofenac sodium salt,

(b) 76.57% (w/w) of water,

(c) 10.0% (w/w) of isopropanol,

(d) 5.0% (w/w) of propylene glycol,

(e) 0.7% (w/w) of Carbomer 980,

(f′) 2.5% (w/w) of liquid paraffin,

(f″) 2.5% (w/w) of coco-caprylate/caprate,

(g) 2.0% (w/w) polyoxethylene-20-cetostearyl ether, and

(h) 0.63% (w/w) ammonia, concentrated solution in water.

2. A pharmaceutical composition in the form of an emulsion gel for topical use consisting of:

(a) 0.10% (w/w) of diclofenac sodium salt,

(b) 74.9% (w/w) of water,

(d) 15.0% (w/w) of propylene glycol,

(e) 1.0% (w/w) of Carbomer 974P,

(f′) 2.5% (w/w) of liquid paraffin,

(f″) 2.5% (w/w) of coco-caprylate/caprate,

(g) 2.0% (w/w) polyoxethylene-20-cetostearyl ether,

(h) 1.5% (w/w) 30% aqueous NaOH solution, and

(i) 0.5% (w/w) benzyl alcohol.

3. A pharmaceutical composition in the form of a sprayable emulsion gel consisting of:

(a) 0.10% (w/w) of diclofenac sodium salt,

(b) 86.68% (w/w) of water,

(d) 5.0% (w/w) of propylene glycol,

(e) 0.3% (w/w) of Carbomer 974P,

(f′) 2.5% (w/w) of liquid paraffin,

(f″) 2.5% (w/w) of coco-caprylate/caprate,

(g) 2.0% (w/w) polyoxethylene-20-cetostearyl ether,

(h) 0.42% (w/w) 30% aqueous NaOH solution, and

(i) 0.5% (w/w) benzyl alcohol.

Assignments (4)
CHANGE OF NAME Recorded Mar 1, 2024
From: GSK CONSUMER HEALTHCARE SARL
To: HALEON CH SARL
Reel/Frame 066618/0404 →
CHANGE OF LEGAL ENTITY Recorded Apr 12, 2022
From: GSK CONSUMER HEALTHCARE S.A.
To: GSK CONSUMER HEALTHCARE SARL
Reel/Frame 059678/0841 →
CHANGE OF NAME Recorded Jan 31, 2020
From: NOVARTIS CONSUMER HEALTH S.A.
To: GSK CONSUMER HEALTHCARE S.A.
Reel/Frame 051889/0465 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2013
From: STEIGER, MICHEL
To: NOVARTIS CONSUMER HEALTH S.A.
Reel/Frame 030976/0052 →